Tibulizumab (LY 3090106) is a Tetravalent Bispecific mAb Targeting BAFF and IL-17A
B-cell-activating factor (BAFF) is a member of the tumour-necrosis factor (TNF) family. BAFF is a trimeric membrane-bound or soluble factor. BAFF binds to three receptors: BCMA (B-cell maturation antigen), TACI…